Cell Bio Human Tech Co., Ltd

Cell Bio Human Tech Co., Ltd

KKRX:318160
5,050.00
KRW
-410.00
(-7.51%)
1,202.60EPS
4.72P/E
49.00BMarket Cap

Total Valuation

KRW

As of June 30, 2026, Cell Bio Human Tech Co., Ltd carries a market capitalization of 49.00B, placing it among publicly traded companies globally. Its enterprise value stands at 60.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap49.00B
Enterprise Value60.69B

Share Statistics

As of June 30, 2026, Cell Bio Human Tech Co., Ltd has 8.38M shares outstanding.

Shares Outstanding8.38M

Valuation Ratios

As of June 30, 2026, Cell Bio Human Tech Co., Ltd trades at a trailing price-to-earnings ratio of 4.72. The price-to-sales ratio is 0.82, and the price-to-book ratio stands at 0.80.

PE Ratio4.72
PS Ratio0.82
PB Ratio0.80
P/TBV Ratio0.83
P/FCF Ratio-7.34
P/OCF Ratio7.36

Enterprise Valuation

As of June 30, 2026, Cell Bio Human Tech Co., Ltd trades at an EV/EBITDA multiple of 4.74 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 6.21 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 60.69B versus a market cap of 49.00B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.00
EV / EBITDA4.74
EV / EBIT6.21

Financial Position

As of June 30, 2026, Cell Bio Human Tech Co., Ltd maintains a current ratio of 2.87, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.00, indicating elevated leverage, while an interest coverage ratio of 14.25 demonstrates strong ability to service its debt obligations.

Current Ratio2.87
Quick Ratio0.81
Debt / Equity33.00
Debt / EBITDA1.64
Interest Coverage14.25

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, Cell Bio Human Tech Co., Ltd posted a return on equity (ROE) of 19.68, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 13.72 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.44, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.04, useful for judging operating efficiency across full business cycles. The company generates approximately 698.00M in revenue per employee across its workforce of 87.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.74 indicates how many times Cell Bio Human Tech Co., Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)19.68
Return on Assets (ROA)14.44
Return on Invested Capital (ROIC)13.72
Return on Capital Employed (ROCE)17.04
Revenue Per Employee698.00M
Employee Count87.25
Inventory Turnover3.74

Taxes

KRW

Over the twelve months ended June 30, 2026, Cell Bio Human Tech Co., Ltd recorded 475.14M in income tax expense. That works out to an effective tax rate of 4.35, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.93B, leaving 10.57B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax475.14M
Effective Tax Rate4.35

Stock Price Statistics

KRW

As of the close on November 17, 2026, Cell Bio Human Tech Co., Ltd's stock has declined approximately 40.24% over the past 52 weeks. The 50-day moving average sits at 6,424.60, while the 200-day moving average is 6,713.20.

52-Week Price Change-40.24%
50-Day Moving Average6,424.60
200-Day Moving Average6,713.20

Income Statement

KRW

Over the twelve months ended June 30, 2026, Cell Bio Human Tech Co., Ltd generated 60.90B in revenue and converted that into 10.57B in net income, yielding earnings per share of 1,202.60. EBITDA reached 12.80B, while operating income came in at 9.78B.

Revenue60.90B
Gross Profit20.32B
Operating Income9.78B
Pretax Income10.93B
Net Income10.57B
EBITDA12.80B
EBIT9.78B
Earnings Per Share (EPS)1,202.60

Balance Sheet

KRW

As of June 30, 2026, Cell Bio Human Tech Co., Ltd holds 11.91B in cash and equivalents against 20.98B in total debt, resulting in a net debt position of 9.42B. Total book value stands at 60.95B, with working capital of 27.32B providing operational flexibility.

Cash & Cash Equivalents11.91B
Total Debt20.98B
Net Debt9.42B
Equity (Book Value)60.95B
Book Value Per Share7,277.24
Working Capital27.32B

Cash Flow

KRW

Cell Bio Human Tech Co., Ltd produced 6.77B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -13.70B in capital expenditures, free cash flow totaled -6.93B - equivalent to -812.81 per share.

Operating Cash Flow6.77B
Capital Expenditures-13.70B
Free Cash Flow-6.93B
FCF Per Share-812.81

Margins

Over the twelve months ended June 30, 2026, Cell Bio Human Tech Co., Ltd posted a gross margin of 33.36, reflecting its pricing power and cost economics. The operating margin of 16.05 and net profit margin of 17.35 provide insight into operational efficiency.

Gross Margin33.36
Operating Margin16.05
Pretax Margin17.95
Profit Margin17.35
EBITDA Margin21.02

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -13.62: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.92, meaning Cell Bio Human Tech Co., Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-15.92
FCF Yield-13.62

Scores

As of June 30, 2026, Cell Bio Human Tech Co., Ltd has an Altman Z-Score of 2.92, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.92